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Summary 
 
 One backgrounding field study was con-
ducted at two locations to compare the health 
and performance of high-risk receiving steers 
given an ExpressTM 5-Pasteurella Haemo-
lytica-Multocida (PHM) vaccine or a Tita-
nium® 5-PHM Bac®-1 vaccine.  At one loca-
tion, calves given the Titanium 5-PHM vacci-
nation had fewer first and second repulls 
(P<0.05).  At the other location, calves given 
the Express 5-PHM vaccination had fewer ini-
tial pulls for respiratory disease and more hos-
pital pen days at initial pull (P<0.05) than 
those given Titanium 5-PHM.  No differences 
were measured at either location for mortality 
and average daily gain.  
 
Introduction 
 
 Throughout the marketing chain, beef cat-
tle can be introduced to many types of stress-
ors and degrees of trauma, such as weaning, 
exposure to pathogens and handling at sale-
barns, and long-distance hauling.  Cattle that 
are “high-risk” have experienced many exces-
sive-trauma stressors over an extended period 
and are classified as likely to acquire Bovine 
Respiratory Disease complex (BRD).  This 
disease is ranked first among all disease con-
ditions in U.S. feedyards (NAHMS, 1999) and 
accounts for millions of dollars of loss to pro-
ducers every year. 
 
 There are several types of BRD, pneumo-
nia being the most prevalent form.  Three fac-
tors must be present for pneumonia to de-
velop:  (1) stress, (2) viral infection, and (3) 
bacterial infection.  To help prevent the onset 
of a viral infection, a modified live vaccine 
with common respiratory antigen components 
is used.  Common respiratory viruses in cattle 
include infectious bovine rhinotracheitis 
(IBR), parainfluenza 3 (PI3), bovine virus di-
arrhea (BVD) type I and II, and bovine respi-
ratory syncytial virus (BRSV).  Two of the 
most predominate types of bacterial infections 
involved in pneumonia are Mannheimia (Pas-
teurella) haemolytica (PHM) and Pasteurella 
multocida.   
 
 The objective of this study was to evaluate 
two different modified live virus-pasteurella 
combination vaccines, Express 5-PHM and 
Titanium 5-PHM, on subsequent health and 
performance of seriously stressed steers.  Both 
vaccines contain the same five modified live 
viral components:  IBR, PI3, BVD type I and 
II, and BRSV.  The vaccines differ in the form 
of the Pasteurella haemolytica-multocida 
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component:  Express 5-PHM is in a killed 
form, whereas in Titanium 5-PHM it is in a 
modified live form. 
 
Experimental Procedures 
 
 Location 1.  A total of 736 steers (average 
352 lb initial body weight) from the southeast-
ern United States, were used at location 1 in 
East-Central Kansas.  These cattle were poorer 
quality, light-weight, and high-risk calves.  
Animals were randomly assigned to vaccine 
treatments and given a metaphylactic treat-
ment of Micotil®, an endectocide pour-on, 
Revalor®-G growth implant, and were cas-
trated/dehorned upon arrival.  The cattle were 
not assigned vaccine treatments on the basis of 
castration status at time of arrival.  Approxi-
mately 10 days later, a booster of the original 
vaccine product without the Pasteurella 
haemolytica- multocida component was given 
to all steers except those in the hospital pen.  
Sick animals were pulled and treated accord-
ing to the standard protocol in use at this loca-
tion.  All cattle were fed a high-energy diet 
based on corn silage.  Uniform health and 
management procedures were used throughout 
the study.  A final weight was taken of all 
steers after an average of 93 days. 
 
 Location 2.  All treatments and proce-
dures at location 2 were the same as those 
used at location 1, except that a 7-way clos-
tridial vaccine and a Synovex®-S growth im-
plant were given at initial processing.  A total 
of 422 steers (average 532 lb initial body 
weight) originating from the southeastern 
United States were used at location 2, which 
was also in East-Central Kansas.  These cattle 
were better quality than those at location 1 and 
carried moderate flesh, but they were still con-
sidered to be high-risk calves.  A final weight 
was taken of all steers after an average of 84 
days.  
 
Results and Discussion 
 
 Health and performance data for the loca-
tions were not pooled because of the wide 
range of differences in cattle quality and asso-
ciated risk level.  At location 1, there were 
fewer first repulls (P<0.05) of non-castrate 
calves (steers upon arrival) that had been 
given the Titanium 5-PHM treatment (Table 
1). There were fewer second repulls (P<0.05) 
of castrates (bulls upon arrival).  There were 
no other significant differences among treat-
ments at location 1 for initial pulls for respira-
tory disease, hospital pen days, percentage 
death loss, and average daily gain.  
 
 At location 2, there were fewer initial pulls 
for respiratory disease and more average hos-
pital days when initially pulled (P<0.05) in 
non-castrate calves (steers upon arrival) that 
had been given the Express 5-PHM treatment 
(Table 2). There were no other significant dif-
ferences for the remaining measurements 
taken at location 2.  
 
 Because performance between non-
castrates (steers) and castrates (bulls) upon 
arrival was not the primary focus of this study, 
statistical analyses were not conducted for 
these differences.  Differences can be seen, 
however, in initial pulls, death loss, and aver-
age daily gain.  These differences were par-
ticularly marked for the cattle type used at lo-
cation 1. 
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Table 1.  Performance Differences Between Express 5-PHM Vaccine and Titanium 5-PHM Vac-
cine on % Pulls for Respiratory Disease, Treatment Days in Hospital Pen for Each Pull Occasion, 
% Death Loss, and Average Daily Gain at Location 1 
 Non-Castrate (Steers)a  Castrate (Bulls) 
Item ExpressTM Titanium®  ExpressTM Titanium® 
Head 89 74 282 291 
     
Initial Pulls, %* 38.8 23.3 51.2 54.5 
First Repulls, %* 22.3b 9.1c 23.4 26.4 
Second Repulls, %* 5.6 1.1 9.2b 4.2c 
     
Average Hospital Days     
   Initial Pulls* 5.1 4.5 5.1 5.4 
   First Repulls* 5.4 5.1 4.5 4.7 
   Second Repulls* 4.3 1.3 3.9 4.2 
     
Death Loss, %* 7.1 10.0 16.3 18.0 
     
Daily gain, lb* 2.0 2.2 1.7 1.8 
aData analyzed separately according to castration status upon arrival. 
bcDifferent superscripts between vaccines differ (P<0.05). 
*Means blocked by load. 
 
 
Table 2.  Performance Differences Between Express 5-PHM Vaccine and Titanium 5-PHM Vac-
cine on % Pulls for Respiratory Disease, Treatment Days in Hospital Pen for Each Pull Occasion, 
% Death Loss, and Average Daily Gain at Location 2 
 Non-Castrate (Steers)a  Castrate (Bulls) 
Item ExpressTM Titanium®  ExpressTM Titanium® 
Head 52 58 162 150 
     
Initial Pulls, %* 23.1b 43.1c 42.0 48.0 
First Repulls, %* 3.5 13.0c 16.0 16.0 
Second Repulls, %* 0.5 8.3 5.6 4.0 
     
Average Hospital Days     
   Initial Pulls* 5.8b 3.5c 4.5 4.7 
   First Repulls* 3.3 4.8 4.2 4.8 
   Second Repulls* 0.0 4.9 3.3 6.2 
     
Death Loss, %* 6.1 2.5 6.1 5.2 
     
Daily gain, lb* 2.7 2.7 2.3 2.2 
aData analyzed separately according to castration status upon arrival. 
bcDifferent superscripts between vaccines differ (P<0.05). 
*Means blocked by load. 
 
